THE NOVARTIS PATENT DISPUTE: OF "SPINS" AND EMPTY RHETORIC
A couple of days back, in a legal dispute involving the patentability of Novartis’s famed anticancer drug, Gleevec, the Madras High Court ruled that section 3(d) of the Indian Patents Act was constitutional. It also held that it lacked jurisdiction to rule on whether or not section 3(d) contravened TRIPS–and that the appropriate forum to adjudicate this issue was the WTO. I’d hinted at the excessive spin on this judgment by interested stakeholders in an earlier blog posting. Let me
THE NOVARTIS PATENT DISPUTE: OF "SPINS" AND EMPTY RHETORIC Read More »






